Health Condition 1: null- Schizophrenia Health Condition 2: F20- Schizophrenia
Conditions
Interventions
Intervention1: Valacyclovir
: Patients randomized to VAV arm will receive 1.5 g by mouth, twice daily. This dose is identical to the SMRI/PITT trial
it is adequate for suppressive HSV-1 therapy (http://www.drugs.com/pro/valacyclovir.html). Subjects will receive either VAV or placebo for 16 weeks, after which both groups will be followed up withou
Sponsors
The Stanley Medical Research Institute
Eligibility
Inclusion criteria
Inclusion criteria: • Written informed consent. • Both genders, ages 18-50 years • Schizophrenia / schizoaffective disorder (DSM IV). • Duration of psychosis • Stable dose of antipsychotic for > 1 month, continued throughout the study. • Score 4 or more on one or more items of the Positive and Negative Syndrome Scale. • Exposed to HSV-1: serum antibody assays.
Exclusion criteria
Exclusion criteria: • Substance abuse in the past month/dependence past 6 months. • History / current medical /neurological illnesses e.g., epilepsy. • Pregnancy. • History of immune disorders, HIV infection, or receiving immune-suppressants. • Receiving regular antiviral therapy. • History of hypersensitivity to Valacyclovir. • Mental retardation as defined in DSM IV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To Improve cognitive function among HSV-1 exposed Early Course Schizophrenia patients.Timepoint: Baseline, zero week, 2 week, 4 week, 8 week, 12 week, 16 week, 20 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall daily functions among HSV-1 exposed Early course schizophreniaTimepoint: Baseline, zero week, 2 week, 4 week, 8 week, 12 week, 16 week, 20 week | — |
Countries
India
Contacts
Public ContactProf Smita N Deshpande
PGIMER-Dr.R.M.L.Hospital
Outcome results
None listed